16 July 2024 - Pharmaceutical giants Johnson & Johnson, BMS and AstraZeneca are rejecting federal district court decisions that rule a government drug price-setting program is constitutional and voluntary.

Opening briefs from Johnson & Johnson and Bristol Myers filed 12 July before the US Court of Appeals for the Third Circuit challenge an April decision from a federal judge in New Jersey that tossed the manufacturers’ claims that the Medicare Drug Price Negotiation Program violates the First Amendment compelled speech doctrine and Fifth Amendment takings clause.

Read Bloomberg article